Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, RHYTHM PHARMACEUTICALS, INC. reported revenue of $190M, up 45.8% year over year. Operating margin was -101.2% and net margin -103.6%, on a free-cash-flow margin of -61.5% with capital expenditure at 0.5% of revenue. Every figure is computed directly from RYTM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $190M | -101.2% | -103.6% |
| FY2024 | $130M | -204.0% | -200.3% |
| FY2023 | $77M | -238.1% | -238.5% |
| FY2022 | $24M | -757.9% | -766.2% |
| FY2021 | $3M | -5391.9% | -2207.1% |
How does RYTM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.